-
Mashup Score: 1
DENVER — The concomitant use of atogepant for preventive and ubrogepant for acute migraine treatment was found to be safe and well-tolerated over 12 weeks, according to research presented at the American Academy of Neurology annual meeting.Patients often take atogepant for prevention of migraine plus ubrogepant for acute treatment, Jessica Ailani, MD, director of the MedStar Georgetown
Source: www.healio.comCategories: General Medicine News, General NewsTweet
Concomitant #atogepant for preventive and #ubrogepant for acute #migraine treatment was found to be safe and well-tolerated over 12 weeks, according to a presenter at #AANAM. Read more from @MedStarGUH, presented at @AANmember annual meeting: https://t.co/PYXA6yOGr3